Preclinical Assets Global Market Report 2024

A preclinical asset encompasses all clinical trial supplies or equipment utilized during the preclinical development phase, bridging the gap between drug discovery in the laboratory and the commencement of human clinical trials. This preliminary stage involves essential feasibility assessments, iterative evaluations, and the gathering of safety data, primarily conducted on laboratory animals.

The primary categories of preclinical asset services include bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK studies play a pivotal role in the drug development process, focusing on evaluating the pharmacokinetic and drug metabolism characteristics of potential new drugs. Various models, such as patient-derived organoid (PDO) models and patient-derived xenograft models, are employed by diverse end-users, including biopharmaceutical companies, government institutes, and others.

The preclinical assets market research report is one of a series of new reports from The Business Research Company that provides preclinical assets market statistics, including preclinical assets industry global market size, regional shares, competitors with a preclinical assets market share, detailed preclinical assets market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. This preclinical assets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preclinical assets market size has grown strongly in recent years. It will grow from $5.32 billion in 2023 to $5.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth observed in the historic period can be ascribed to the evolving needs in drug development, advancements in biotechnology, increasing regulatory requirements, growth in research funding, and collaborative efforts in research.

The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $8.34 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine and personalized therapies, integration of artificial intelligence (AI) and machine learning, expansion of biobanking initiatives, a heightened focus on rare diseases, and increased government initiatives and funding. Notable trends expected in the forecast period include the emergence of advanced imaging techniques, utilization of 3D organoid models, integration of multi-omics data, development of enhanced predictive models, and increased automation and high-throughput screening.

The expansion of drug discovery efforts stands as a pivotal driver propelling the growth trajectory of the preclinical asset market. Drug discovery denotes the systematic process of identifying potential chemical compounds suitable for medicinal applications, serving as the initial phase in discovering new therapeutic drugs. Preclinical assets play a critical role within this domain, furnishing vital data and evidence essential for selecting promising molecules for subsequent clinical development. For instance, reports from the Regulatory Affairs Professionals Society in January 2022 highlighted that in 2021, approximately 74% of drugs approved by the US Food and Drug Administration (FDA) utilized at least one expedited pathway, marking an increase from 68% in the previous year. Additionally, insights from Pharma Intelligence's Pharma R&D Annual Review 2022 in June 2023 showcased growth in the R&D pipeline, with drug numbers rising from 17,737 in 2020 to 20,109 in 2022. Hence, the burgeoning drug discovery efforts fuel the expansion of the preclinical assets market.

The escalating need to mitigate clinical trial expenditures drives the upward momentum of the preclinical asset market. Clinical trial costs encompass the comprehensive expenses incurred in planning, executing, and managing trials aimed at assessing the safety, efficacy, and potential benefits of novel medical interventions. These trials provide critical insights into the safety, effectiveness, and potential side effects of preclinical assets, validating their therapeutic promise in human subjects. For instance, data sourced from Genetic Engineering and Biotechnology News in February 2023 underscored a substantial rise in the cost of developing new drugs among the top 20 global biopharma companies, soaring by 15% from $298 million in 2022 to approximately $2.3 billion in 2023. This increase encapsulates the expenses incurred throughout the drug development lifecycle, particularly in clinical trial phases. Hence, the mounting emphasis on reducing clinical trial costs propels the expansion of the preclinical asset market.

Product innovation has emerged as a significant trend driving growth within the preclinical assets market. Prominent players in this sector are heavily invested in pioneering new products and solutions to fortify their market position and gain a competitive edge. An illustrative case is the partnership between Charles River Laboratories International and Valo Health Inc. In April 2022, they introduced Logica, an AI-powered drug solution. This innovative offering seamlessly translates biological insights of clients into optimized preclinical assets. By amalgamating Charles River's extensive preclinical expertise with Valo's AI-driven Opal Computational Platform, Logica delivers a unified approach to drug discovery. This transformative partnership ensures the conversion of targets into candidate nominations, enhancing efficiency and yielding highly qualified leads for clients while aligning costs with value creation.

Strategic partnerships stand as a burgeoning trend shaping the landscape of the preclinical assets market. Leading entities operating in this domain are actively forging strategic alliances to bolster their market standing. An exemplar of this trend is the extended collaboration between AbbVie, a US-based pharmaceutical company, and Calibr, renowned for its prowess in research and drug development. This extended collaboration stems from the alliance between AbbVie and Scripps Research. Under this expanded partnership, Calibr is set to present AbbVie with new discovery targets and preclinical assets, aligning with mutual interests for potential options. This strategic collaboration enables both entities to continue advancing innovative preclinical and early-stage clinical assets, fostering an environment of growth and development within the market.

In October 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation based in the United States, completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for a total of $11.6 billion. Through this acquisition, Pfizer obtained access to a promising portfolio of calcitonin gene-related peptide (CGRP) receptor antagonists, which encompasses Rimegepant, Zavegepant, and a collection of preclinical CGRP assets. Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company headquartered in the United States, known for its early-stage discovery program and various preclinical assets.

Major companies operating in the preclinical assets market report are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

North America was the largest region in the preclinical assets market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the preclinical assets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preclinical Assets Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preclinical assets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preclinical assets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The preclinical assets market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies; Toxicology Testing; Compound Management; Safety Pharmacology; Other Services
• 2) By Model Type: Patient Derived Organoid (PDO) Model; Patient Derived Xenograft Model
• 3) By End User: Biopharmaceutical Companies; Government Institutes; Other End-Users
• Companies Mentioned: Laboratory Corporation of America; IQVIA Inc.; ICON PLC; Eurofins Scientific SE; PPD Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.